Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
3688 Comments
1517 Likes
1
Boedy
Daily Reader
2 hours ago
The passion here is contagious.
👍 205
Reply
2
Drewcilla
Returning User
5 hours ago
Did you just bend reality with that? 🌌
👍 103
Reply
3
Wray
Trusted Reader
1 day ago
This is exactly what I needed… just not today.
👍 215
Reply
4
Jessical
Regular Reader
1 day ago
Exceptional results, well done!
👍 86
Reply
5
Camrynne
Returning User
2 days ago
Execution at its finest.
👍 221
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.